Sotera Health Co is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$25
Forward price-to-earnings vs peers
Base case. Range ~$20–$34. Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings.
No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.
Sotera Health Co valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $1.22bn, up 8.1% on a year earlier, faster than 7.4% a quarter earlier. Free-cash-flow margin held at 9.3%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 6 financial-health checks. Our cash-flow model value is $-1.81 a share, against a share price of $18.04.
Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Sotera Health Co's trailing-twelve-month revenue grew 8.1% year on year, with a free-cash-flow margin of 9.3%. Where it stands out: net margin of 13.4% ranks 10 of 54 life sciences tools & services companies we cover. Where it lags: long-term debt as % of assets of 64.3% ranks 34 of 35 life sciences tools & services companies we cover.
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 0.0% while net income grew 580.5%: a 581pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The company also guided to net revenues growth outlook of 5.25 to 6.75 for the full-year 2026; adjusted ebitda of $634.00m to $643.00m for the 2026.
Our value per share comes from a discounted-cash-flow model of Sotera Health Co's free cash flow after stock-based pay ( $53.7M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.
We value Sotera Health Co as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.01 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$3.5 ~$0.8–$5.5 | Left out: out of range vs price (0.20x) |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$25 ~$20–$34 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | ~$0.7 ~$0.5–$1.2 | Left out: out of range vs price (0.04x) |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity below long-run growth |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: earnings are positive: price-to-earnings is the better measure |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$25 ~$20–$34 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sotera Health Co with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|
| Share price | $27.44 | $23.55 | $8.33 | $16.85 | $13.68 | $17.64 | $17.74 |
| Market value | $6.5bn | $6.6bn | $2.3bn | $4.8bn | $3.9bn | $5.1bn | $5.1bn |
| + Net debt (− = net cash) | $1.8bn | $1.7bn | $1.6bn | $2.0bn | $2.0bn | $1.8bn | $1.8bn |
| Enterprise value | $8.3bn | $8.2bn | $3.9bn | $6.7bn | $5.9bn | $6.9bn | $6.9bn |
| Multiples | |||||||
| Price / sales | 8.0x | 7.1x | 2.3x | 4.5x | 3.5x | 4.3x | 4.2x |
| Price / earnings | — | 56.3x | — | 92.9x | 87.8x | 64.8x | 31.3x |
| Price / free cash flow | 97.2x | 36.7x | 24.4x | — | 86.4x | 33.9x | 45.3x |
| EV / EBITDA | 30.8x | 25.7x | 12.5x | 19.1x | 15.4x | — | — |
Strong moat
How hard Sotera Health's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median 11.3% of total assets over 5 years.
Gross margin has been a median 55.2%, moving by 0.5 percentage points (standard deviation) across 6 years.
Operating margin has been a median 26.4%; its worst year was 24.7%.
Free cash flow was positive in 5 of 6 years, at a median 9.6% of revenue.
The diluted share count rose 10.3% over five years; stock-based pay has been a median 2.8% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (77 before it).
Next results: November 3, 2026, before the open. Analysts expect revenue of $320m and EPS of $0.27 (range $0.26 to $0.27) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $0.98 | +14% | $1.2bn | +7% |
| Next | $1.07 | +9% | $1.3bn | +6% |
Next year's EPS estimate has moved +1.4% in 90 days, across 10 analysts.
The consensus EPS forecast for the current fiscal year is +1.8% on 90 days ago. In the last 30 days, 1 analyst raised Sotera Health Co's forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $0.97 | $1.06 |
| 60 days ago | $0.98 | $1.07 |
| 30 days ago | $0.98 | $1.07 |
| 7 days ago | $0.98 | $1.07 |
| Now | $0.98 | $1.07 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.24 | $0.26 | +8.7% |
| Mar 2026 | $0.17 | $0.18 | +3.4% |
| Dec 2025 | $0.24 | $0.26 | +7.0% |
| Sept 2025 | $0.22 | $0.26 | +19.1% |
Adjusted EPS as companies report it, against the average analyst estimate.
Our cash-flow model grows Sotera Health Co's revenue by +6.2% next year and +7.2% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+5.6%, weight 54%) , management guidance (+5.5%, weight 20%) and the company's own record (+7.9%, weight 26%) . How the weights are set.
Last 12 months +6.9%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $1.1bn | $1.2bn | +8.1% |
| Net margin | 2.1% | 13.4% | +529.2% |
| P/E multiple | 197.0x | 31.3x | −84.1% |
| Share count | 285m | 288m | −1.0% |
Biggest factor: p/e multiple.
Last 3 years +34.3%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $976m | $1.2bn | +24.6% |
| P/S multiple | 3.8x | 4.2x | +10.3% |
| Share count | 282m | 288m | −2.2% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| SHC | −14% | −65% | +102% | −19% | +29% | +1% |
| Industry peers (median) | +5% | −51% | −3% | −13% | −7% | +16% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| SHC | 50% | 33% | 50% | 50% | 58% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| SHC | −29% | −75% | −35% | −38% | −30% | −32% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 20, 2020: 80% from March 12, 2021 to November 17, 2022. Getting back needed a 387% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | +4.9% | +0.5% | +5.8% | +5.1% |
| May 5, 2026 | +2.7% | +2.2% | +1.6% | +1.2% |
| February 24, 2026 | −7.6% | +1.6% | −10.2% | −21.7% |
| January 12, 2026 | −1.1% | 0.0% | −2.7% | −9.5% |
| November 4, 2025 | −4.8% | −0.8% | −2.9% | −0.3% |
| August 8, 2025 | +25.3% | +0.6% | +40.3% | +40.9% |
| May 1, 2025 | +7.7% | +2.2% | +15.0% | +6.0% |
| February 27, 2025 | −8.6% | −0.1% | −11.7% | −13.7% |
| January 14, 2025 | −4.0% | +2.0% | +3.9% | +2.6% |
| November 5, 2024 | +2.0% | +3.7% | −1.6% | −17.9% |
| August 5, 2024 | +11.2% | −2.0% | +8.1% | +16.6% |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $990.6M |
| FY23 Q4 | $1B |
| FY24 Q1 | $1.1B |
| FY24 Q2 | $1.1B |
| FY24 Q3 | $1.1B |
| FY24 Q4 | $1.1B |
| FY25 Q1 | $1.1B |
| FY25 Q2 | $1.1B |
| FY25 Q3 | $1.2B |
| FY25 Q4 | $1.2B |
| FY26 Q1 | $1.2B |
| FY26 Q2 | $1.2B |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | -0.3% |
| FY23 Q4 | 4.5% |
| FY24 Q1 | 9.0% |
| FY24 Q2 | 12.5% |
| FY24 Q3 | 13.1% |
| FY24 Q4 | 4.9% |
| FY25 Q1 | 2.8% |
| FY25 Q2 | 2.4% |
| FY25 Q3 | 2.7% |
| FY25 Q4 | 5.7% |
| FY26 Q1 | 7.4% |
| FY26 Q2 | 8.1% |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY22 Q1 | 27.6% |
| FY22 Q2 | 26.5% |
| FY22 Q3 | 25.6% |
| FY22 Q4 | 24.7% |
| FY23 Q1 | 23.1% |
| FY23 Q2 | 22.5% |
| FY23 Q3 | 23.5% |
| FY23 Q4 | 26.4% |
| FY24 Q1 | 27.5% |
| FY24 Q2 | 28.2% |
| FY24 Q3 | 28.1% |
| FY24 Q4 | 27.0% |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -38.4% |
| FY23 Q4 | -34.6% |
| FY24 Q1 | -35.0% |
| FY24 Q2 | 2.9% |
| FY24 Q3 | 9.2% |
| FY24 Q4 | 4.1% |
| FY25 Q1 | 9.6% |
| FY25 Q2 | 10.0% |
| FY25 Q3 | 7.5% |
| FY25 Q4 | 12.8% |
| FY26 Q1 | 8.1% |
| FY26 Q2 | 9.3% |
| Fiscal year | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 778 | 818 | 931 | 1,004 | 1,049 | 1,100 | 1,164 | 1,216 |
| Gross profit | 395 | 444 | 519 | 557 | 577 | 602 | 646 | 669 |
| EBITDA | 250 | 269 | 321 | 313 | 353 | 382 | — | — |
| Operating income | 184 | 206 | 257 | 248 | 277 | 298 | — | — |
| Net income | −21 | −39 | 117 | −234 | 51 | 44 | 78 | 163 |
| Diluted EPS | −$0.09 | −$0.16 | $0.41 | −$0.83 | $0.18 | $0.16 | $0.27 | $0.57 |
| Growth (year on year) | ||||||||
| Revenue | — | +5.1% | +13.9% | +7.8% | +4.5% | +4.9% | +5.7% | +8.1% |
| EBITDA | — | +7.6% | +19.2% | −2.6% | +13.0% | +8.1% | — | — |
| Operating income | — | +12.2% | +24.6% | −3.3% | +11.4% | +7.6% | — | — |
| Net income | — | — | — | −299.8% | — | −13.6% | +75.6% | +580.5% |
| Diluted EPS | — | — | — | −302.4% | — | −11.1% | +68.8% | +573.5% |
| Margins | ||||||||
| Gross margin | 50.8% | 54.2% | 55.7% | 55.5% | 55.0% | 54.7% | 55.5% | 55.0% |
| EBITDA margin | 32.2% | 32.9% | 34.5% | 31.2% | 33.7% | 34.7% | — | — |
| Operating margin | 23.6% | 25.2% | 27.6% | 24.7% | 26.4% | 27.0% | — | — |
| Net margin | −2.7% | −4.7% | 12.5% | −23.3% | 4.9% | 4.0% | 6.7% | 13.4% |
| Free-cash-flow margin | 11.8% | 8.2% | 19.3% | 9.5% | −34.6% | 4.1% | 12.8% | 9.3% |
| Cash flow | ||||||||
| Cash from operations | 149 | 121 | 282 | 278 | −148 | 224 | 287 | 292 |
| Capital spending | 57 | 54 | 102 | 182 | 215 | 179 | 138 | 179 |
| Free cash flow | 92 | 67 | 179 | 96 | −363 | 45 | 149 | 113 |
| Stock-based pay | 7 | 11 | 14 | 21 | 32 | 37 | 31 | 37 |
| Free cash flow after stock pay | 85 | 56 | 166 | 74 | −395 | 8 | 118 | 76 |
| Balance sheet | ||||||||
| Cash | 63 | 102 | 107 | 395 | 296 | 277 | 345 | 357 |
| Total debt | 0 | 1,864 | 1,764 | 1,964 | 2,261 | 2,256 | 2,169 | 2,166 |
| Net debt (negative = net cash) | −63 | 1,761 | 1,657 | 1,568 | 1,964 | 1,978 | 1,825 | 1,809 |
| Diluted shares | 232m | 238m | 279m | 280m | 283m | 285m | 286m | 288m |
| Returned to shareholders | ||||||||
| Dividends | 691 | 0 | 0 | — | — | — | — | — |
| Buybacks | 0 | 34 | 0 | 0 | — | — | — | — |
| Total returned | 691 | 34 | 0 | 0 | — | — | — | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 285 | 290 | 255 | 294 | 311 | 303 | 280 | 321 |
| Gross profit | 158 | 164 | 135 | 167 | 178 | 166 | 147 | 178 |
| EBITDA | 104 | 108 | — | — | — | — | — | — |
| Operating income | 81 | 87 | — | — | — | — | — | — |
| Net income | 17 | 12 | −13 | 8 | 48 | 35 | 27 | 54 |
| Diluted EPS | $0.06 | $0.05 | −$0.05 | $0.03 | $0.17 | $0.12 | $0.09 | $0.19 |
| Growth (year on year) | ||||||||
| Revenue | +8.5% | −6.5% | +2.6% | +6.4% | +9.1% | +4.6% | +10.0% | +9.2% |
| EBITDA | +10.2% | −13.5% | — | — | — | — | — | — |
| Operating income | +5.8% | −16.2% | — | — | — | — | — | — |
| Net income | — | −68.1% | −310.4% | −9.0% | +184.7% | +182.8% | — | +573.7% |
| Diluted EPS | — | −64.3% | −350.0% | 0.0% | +183.3% | +140.0% | — | +533.3% |
| Margins | ||||||||
| Gross margin | 55.4% | 56.6% | 53.2% | 56.6% | 57.0% | 54.7% | 52.5% | 55.4% |
| EBITDA margin | 36.3% | 37.2% | — | — | — | — | — | — |
| Operating margin | 28.2% | 30.0% | — | — | — | — | — | — |
| Net margin | 6.0% | 4.2% | −5.2% | 2.7% | 15.5% | 11.5% | 9.5% | 16.7% |
| Free-cash-flow margin | 21.4% | −3.5% | 14.0% | 8.9% | 11.2% | 17.3% | −6.0% | 13.1% |
| Cash flow | ||||||||
| Cash from operations | 97 | 56 | 56 | 57 | 71 | 103 | 29 | 88 |
| Capital spending | 36 | 66 | 20 | 31 | 36 | 51 | 46 | 46 |
| Free cash flow | 61 | −10 | 36 | 26 | 35 | 52 | −17 | 42 |
| Stock-based pay | 10 | 8 | 7 | 8 | 8 | 8 | 14 | 7 |
| Free cash flow after stock pay | 51 | −18 | 28 | 18 | 27 | 45 | −31 | 35 |
| Last 12 months unless stated | SHC | TECH | RGEN | NEO | QGEN | TXG | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $1.2bn | $1.2bn | $806m | $788m | $2.1bn | $617m | $229m |
| Revenue growth, last 12 months | 8.1% | −0.4% | 13.8% | 11.1% | 5.7% | −4.3% | 6.9% |
| Revenue growth, 3-year average | 7.6% | 2.2% | 7.3% | 11.1% | 17.1% | 2.8% | 2.9% |
| Revenue growth, latest quarter | 9.2% | 1.3% | 10.9% | 11.4% | — | −12.6% | 8.5% |
| Gross margin | 55.0% | 65.8% | 53.5% | 44.8% | 62.2% | 70.0% | 51.9% |
| Operating margin | 27.0% | 20.7% | 2.3% | −6.3% | 22.3% | −14.3% | −14.3% |
| Operating margin, 3-year average | 26.1% | 15.6% | 1.4% | −12.5% | 20.4% | −23.3% | −22.4% |
| Net margin | 13.4% | 15.0% | −1.5% | −4.1% | 20.3% | −12.2% | −16.1% |
| Cash from operations / revenue | 24.0% | 24.0% | 16.1% | 0.5% | 31.3% | 20.6% | 1.3% |
| Free-cash-flow margin | 9.3% | 21.7% | 13.2% | −3.6% | 21.7% | 19.7% | −2.2% |
| Free-cash-flow margin, 3-year average | 7.4% | 21.0% | 16.6% | −3.1% | 18.5% | 7.8% | 0.6% |
| Stock pay / revenue | 3.1% | 3.4% | 4.2% | 4.4% | 2.4% | 16.0% | 4.4% |
| Change in share count | 1.0% | −1.7% | 0.3% | 1.2% | −2.6% | 4.2% | 1.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 8.1% | 6.9% | 26 of 54 |
| Change in growth rate Growth | +0.7pp | +0.4pp | 25 of 54 |
| Gross margin Profitability | 55.0% | 52.0% | 18 of 45 |
| Net margin Profitability | 13.4% | -12.2% | 10 of 54 |
| Free-cash-flow margin Cash generation | 9.3% | -1.3% | 18 of 54 |
| Stock pay as % of revenue Cash generation | 3.1% | 4.4% | 20 of 53 |
| Long-term debt as % of assets Balance sheet | 64.3% | 26.3% | 34 of 35 |
| Change in share count Balance sheet | 1.0% | 1.0% | 24 of 46 |
| Days sales outstanding Balance sheet | 45 days | 62 days | 11 of 48 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Sterigenics | $756M | 65.0% | ▲ 8.3% |
| Nelson Labs | $220M | 18.9% | ▼ 3.9% |
| Nordion | $188M | 16.1% | ▲ 8.2% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Services | $996M | 85.6% | ▲ 5.7% |
| Products | $168M | 14.4% | ▲ 5.8% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $630M | 54.1% | ▲ 2.1% |
| Europe | $232M | 20.0% | ▲ 18.5% |
| Canada | $222M | 19.1% | ▲ 6.3% |
| Other Geographical Areas | $79.9M | 6.9% | ▲ 1.4% |
From Sotera Health Co's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Sessa Capital Im, L.P. | $480M | 27.1M | 9.3% | ▲ 17.4% |
| Darsana Capital Partners LP | $479M | 27.0M | 9.3% | ▲ 3.8% |
| Blackrock, Inc. | $429M | 24.1M | 8.3% | ▲ 15.8% |
| Sculptor Capital LP | $426M | 24.0M | 8.3% | ▲ 10.5% |
| Sachem Head Capital Management LP | $276M | 15.6M | 5.4% | ▲ 33.6% |
| Vanguard Capital Management LLC | $216M | 12.2M | 4.2% | ▲ 13.4% |
| Vanguard Portfolio Management LLC | $212M | 11.9M | 4.1% | ▲ 12.6% |
| T. Rowe Price Investment Management, Inc. | $187M | 10.5M | 3.6% | ▲ 15.3% |
| AQR Capital Management LLC | $186M | 10.7M | 3.6% | ▲ 59.7% |
| Jupiter Topco LLC | $149M | 8.4M | 2.9% | — |
| State Street Corp | $148M | 8.3M | 2.9% | ▲ 18.6% |
| FMR LLC | $110M | 6.2M | 2.1% | ▲ 21490.3% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sotera Health Co's complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Petras Michael B. Jr. Executive Chairman | August 17, 2026 | Sell | 850,000 | $18.50 | $15.7M |
| Petras Michael B. Jr. Executive Chairman | August 17, 2026 | Sell | 294,515 | $18.50 | $5.4M |
| Rutz Michael P President of Sterigenics | August 7, 2026 | Sell | 150,000 | $18.84 | $2.8M |
| Gtcr Fund Xi/C Lp Director | May 13, 2026 | Sell | 12,735,301 | $15.17 | $193M |
| Warburg Pincus Xi, L.P. Director | May 13, 2026 | Sell | 19,102,952 | $15.17 | $290M |
| Warburg Pincus (Cayman) Xi, L.P. Director | May 13, 2026 | Sell | 19,102,952 | $15.17 | $290M |
| Gtcr Co-Invest Xi Lp Director | March 6, 2026 | Sell | 10,000,000 | $15.27 | $153M |
| Warburg Pincus Partners Ii, L.P. Director | March 6, 2026 | Sell | 15,000,000 | $15.27 | $229M |
| Warburg Pincus Partners Gp Llc Director | March 6, 2026 | Sell | 15,000,000 | $15.27 | $229M |
| Petras Michael B. Jr. Chairman & CEO | December 8, 2025 | Sell | 39,243 | $16.45 | $645,547 |
| Petras Michael B. Jr. Chairman & CEO | December 8, 2025 | Sell | 394,861 | $16.45 | $6.5M |
| Petras Michael B. Jr. Chairman & CEO | December 8, 2025 | Sell | 315,896 | $16.45 | $5.2M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around January 21, 2027 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
